Breaking News, Collaborations & Alliances

XyloCor Therapeutics, SmartWise Enter License Agreement for Use of Extroducer

XyloCor to deploy the Extroducer to support catheter-based endocardial delivery of its lead gene therapy candidate XC001.

Author Image

By: Charlie Sternberg

Associate Editor

XyloCor Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, and SmartWise, a unit of SmartCella Holding AB, have entered into a licensing agreement under which XyloCor has rights to the Extroducer Infusion Catheter System, an endovascular device designed to deliver advanced therapies directly into the heart and hard-to-reach tissues.  XyloCor plans to deploy the Extroducer to support catheter-based endocardial delivery of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters